Biogen was granted a patent for compounds that degrade BTK.

{
  "signal_id": "6b1b6214-0910-5c82-91c2-09a0fdde03b1",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-09-30T16:58:00+00:00",
  "company": {
    "name": "Biogen",
    "domain": "biogen.com"
  },
  "data": {
    "cpc": [
      {
        "code": "C07D 487/04"
      },
      {
        "code": "A61K 31/53"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Pharmaceuticals",
      "Chemical Engineering"
    ],
    "detail": "In September 2026 Biogen patented drug candidates designed to remove Bruton's tyrosine kinase in cells, for potential use in targeted pharmaceutical treatments.",
    "summary": "Biogen was granted a patent for compounds that degrade BTK.",
    "event_at": "2026-09-29",
    "inventors": [
      {
        "name": "Kevin M. Guckian",
        "status": "resolved",
        "is_primary": true,
        "linkedin_url": "https://www.linkedin.com/in/kevin-guckian-6159275"
      },
      {
        "name": "Eric Stefan",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/eric-stefan-16a5085"
      },
      {
        "name": "Corey Don Anderson",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Jae Young Ahn",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/jae-young-ahn-49668b78"
      },
      {
        "name": "Morgan Welzel O'Shea",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/morgan-welzel-o-shea-69a56023"
      },
      {
        "name": "Jeremy L Yap",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Xinpeng Cheng",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Brian T. Hopkins",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/brian-hopkins-aa159312"
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-09-29",
    "source_url": "https://patents.google.com/patent/US12747241",
    "cpc_primary": {
      "code": "C07D 487/04"
    },
    "patent_title": "Compounds for targeting degradation of Bruton's tyrosine kinase",
    "patent_number": "US12747241",
    "uspto_assignee": "BIOGEN MA INC.",
    "patent_abstract": "This disclosure relates to compounds of Formula (A): BTK-L-DSM (A) or a pharmaceutically acceptable salt thereof, wherein DSM is a degradation signaling moiety that is covalently attached to the linker L, L is a linker that covalently attaches BTK to DSM, and BTK is a Btk binding moiety represented by Formula (I) or Formula (II) that is covalently attached to linker L: in which all of the variables are as defined in the application. Compounds or pharmaceutically acceptable salts thereof as described herein are capable of activating the selective ubiqitination of Btk proteins via the ubiquitin-proteasome pathways (UPP) and cause degradation of Btk proteins. The present disclosure also provides methods of treating disorders responsive to modulation of Btk activity and/or degradation of Btk with at least one compound described herein.",
    "precision_class": "structural",
    "invention_explanation": "A compound that connects to BTK and recruits a separate signal so the cell marks the protein for breakdown.",
    "technologies_mentioned": [
      "targeted protein degradation",
      "BTK inhibitors",
      "medicinal chemistry"
    ]
  }
}

curl https://signals.autobound.ai/v1/signals/6b1b6214-0910-5c82-91c2-09a0fdde03b1 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"biogen.com","limit":20}'